GILEAD SCIENCES, INC. Derivative Asset, Fair Value, Amount Offset Against Collateral
GILEAD SCIENCES, INC. (GILD) had Derivative Asset, Fair Value, Amount Offset Against Collateral of $150.00 million as of 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Notes › Offsetting › Offsetting Derivative Assets
us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral · last filed 2017-05-10
- 2017-03-31: Derivative Asset, Fair Value, Amount Offset Against Collateral $150.00M.
- 2016-12-31: Derivative Asset, Fair Value, Amount Offset Against Collateral $299.00M.
- 2016-09-30: Derivative Asset, Fair Value, Amount Offset Against Collateral $0.00.
- 2016-06-30: Derivative Asset, Fair Value, Amount Offset Against Collateral $4.00M.
| Period end | Derivative Asset, Fair Value, Amount Offset Against Collateral |
|---|---|
| 2017-03-31 | $150.00M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $299.00M 10-Q · filed 2017-05-10 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-07 |
| 2016-06-30 | $4.00M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $8.00M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $172.00M 10-K · filed 2017-02-27 |
| 2015-09-30 | $232.00M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $304.00M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $598.00M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $349.00M 10-K · filed 2016-02-24 |
| 2014-09-30 | $212.22M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $399.00K 10-Q · filed 2014-08-04 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-07 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-25 |
| 2013-09-30 | $0.00 10-Q · filed 2013-10-31 |
| 2013-06-30 | $31.52M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $24.67M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $5.18M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |